-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target

Benzinga·10/16/2026 12:37:29
语音播报
Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.